Lonafarnib, Eiger BioPharmaceuticals’ investigational treatment for progeria and progeroid laminopathies, has lost its accelerated assessment status at the European Medicines Agency. The EU marketing authorization application (MAA) for the oral farnesyltransferase inhibitor will now be reviewed under standard timelines.
The US company attributed the change in review status to the EMA's desire to carry out an inspection and to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?